RT Journal Article
SR Electronic
T1 RBD amplicon sequencing of wastewater reveals patterns of variant emergence and evolution
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.12.24310301
DO 10.1101/2024.07.12.24310301
A1 Chen, Xingwen
A1 Balliew, John
A1 Bauer, Cici X.
A1 Deegan, Jennifer
A1 Gitter, Anna
A1 Hanson, Blake M.
A1 Maresso, Anthony W.
A1 Tisza, Michael J.
A1 Troisi, Catherine L.
A1 Rios, Janelle
A1 Mena, Kristina D.
A1 Boerwinkle, Eric
A1 Wu, Fuqing
YR 2024
UL http://medrxiv.org/content/early/2024/07/12/2024.07.12.24310301.abstract
AB Rapid evolution of SARS-CoV-2 has resulted in the emergence of numerous variants, posing significant challenges to public health surveillance. Clinical genome sequencing, while valuable, has limitations in capturing the full epidemiological dynamics of circulating variants in the general population. This study utilized receptor-binding domain (RBD) amplicon sequencing of wastewater samples to monitor the SARS-CoV-2 community dynamics and evolution in El Paso, TX. Over 17 months, we identified 91 variants and observed waves of dominant variants transitioning from BA.2 to BA.2.12.1, BA.4&5, BQ.1, and XBB.1.5. Our findings demonstrated early detection of variants and identification of unreported outbreaks, while showing strong consistency with clinical genome sequencing data at the local, state, and national levels. Alpha diversity analyses revealed significant periodical variations, with the highest diversity observed in winter and the outbreak lag phases, likely due to lower competition among variants before the outbreak growth phase. The data underscores the importance of low transmission periods for rapid mutation and variant evolution. This study highlights the effectiveness of integrating RBD amplicon sequencing with wastewater surveillance in tracking viral evolution, understanding variant emergence, and enhancing public health preparedness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to Teresa T. Alcala at El Paso Water for sample collection and shipping. This work is supported by the PRIME award from the UTHealth Houston School of Public Health, National Institute of Health RADxUP (1U01TR004355-01), and the Texas Epidemic Public Health Institute (TEPHI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors